Systemic sclerosis

被引:530
作者
Allanore, Yannick [2 ]
Simms, Robert [3 ]
Distler, Oliver [4 ]
Trojanowska, Maria [3 ]
Pope, Janet [5 ]
Denton, Christopher P. [6 ,7 ]
Varga, John [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Med, 240 E Huron St, Chicago, IL 60612 USA
[2] Cochin Hosp, Rheumatol Dept A, Paris, France
[3] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA
[4] Univ Zurich Hosp, Div Rheumatol, Zurich, Switzerland
[5] St Josephs Hlth Ctr, Dept Med, London, ON, Canada
[6] UCL, Div Med, London, England
[7] Royal Free Hosp, London, England
基金
瑞士国家科学基金会;
关键词
INTERSTITIAL LUNG-DISEASE; GROWTH-FACTOR-BETA; PULMONARY ARTERIAL-HYPERTENSION; HEALTH-ASSESSMENT QUESTIONNAIRE; 2013 CLASSIFICATION CRITERIA; THICKNESS PROGRESSION RATE; STEM-CELL TRANSPLANTATION; UNIVERSITY-OF-CALIFORNIA; GENOME-WIDE ASSOCIATION; GENETIC RISK-FACTOR;
D O I
10.1038/nrdp.2015.2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic sclerosis is a complex autoimmune disease characterized by a chronic and frequently progressive course and by extensive patient-to-patient variability. Like other autoimmune diseases, systemic sclerosis occurs more frequently in women, with a peak of onset in the fifth decade of life. The exact cause of systemic sclerosis remains elusive but is likely to involve environmental factors in a genetically primed individual. Pathogenesis is dominated by vascular changes; evidence of autoimmunity with distinct autoantibodies and activation of both innate and adaptive immunity; and fibrosis of the skin and visceral organs that results in irreversible scarring and organ failure. Intractable progression of vascular and fibrotic organ damage accounts for the chronic morbidity and high mortality. Early and accurate diagnosis and classification might improve patient outcomes. Screening strategies facilitate timely recognition of life-threatening complications and initiation of targeted therapies to halt their progression. Effective treatments of organ-based complications are now within reach. Discovery of biomarkers - including autoantibodies that identify patient subsets at high risk for particular disease complications or rapid progression - is a research priority. Understanding the key pathogenetic pathways, cell types and mediators underlying disease manifestations opens the door for the development of targeted therapies with true disease-modifying potential. For an illustrated summary of this Primer, visit: http://go.nature.com/lchkcA
引用
收藏
页数:21
相关论文
共 212 条
[1]   Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc [J].
Abraham, D. .
RHEUMATOLOGY, 2008, 47 :V8-V9
[2]   Determinants of Morbidity and Mortality of Systemic Sclerosis in Canada [J].
Al-Dhaher, Firas F. ;
Pope, Janet E. ;
Ouimet, Janine M. .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2010, 39 (04) :269-277
[3]   2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Outperform the 1980 Criteria: Data From the Canadian Scleroderma Research Group [J].
Alhajeri, Hebah ;
Hudson, Marie ;
Fritzler, Marvin ;
Pope, Janet ;
Tatibouet, Solene ;
Markland, Janet ;
Robinson, David ;
Jones, Niall ;
Khalidi, Nader ;
Docherty, Peter ;
Kaminska, Elzbieta ;
Masetto, Ariel ;
Sutton, Evelyn ;
Mathieu, Jean-Pierre ;
Ligier, Sophie ;
Grodzicky, Tamara ;
LeClercq, Sharon ;
Thorne, Carter ;
Gyger, Genevieve ;
Smith, Douglas ;
Fortin, Paul R. ;
Larche, Maggie ;
Baron, Murray .
ARTHRITIS CARE & RESEARCH, 2015, 67 (04) :582-587
[4]   Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB As Novel Risk Loci for Systemic Sclerosis [J].
Allanore, Yannick ;
Saad, Mohamad ;
Dieude, Philippe ;
Avouac, Jerome ;
Distler, Jorg H. W. ;
Amouyel, Philippe ;
Matucci-Cerinic, Marco ;
Riemekasten, Gabriella ;
Airo, Paolo ;
Melchers, Inga ;
Hachulla, Eric ;
Cusi, Daniele ;
Wichmann, H. -Erich ;
Wichmann, Erich ;
Wipff, Julien ;
Lambert, Jean-Charles ;
Hunzelmann, Nicolas ;
Tiev, Kiet ;
Caramaschi, Paola ;
Diot, Elisabeth ;
Kowal-Bielecka, Otylia ;
Valentini, Gabriele ;
Mouthon, Luc ;
Czirjak, Laszlo ;
Damjanov, Nemanja ;
Salvi, Erika ;
Conti, Costanza ;
Mueller, Martina ;
Mueller-Ladner, Ulf ;
Riccieri, Valeria ;
Ruiz, Barbara ;
Cracowski, Jean-Luc ;
Letenneur, Luc ;
Dupuy, Anne Marie ;
Meyer, Oliver ;
Kahan, Andre ;
Munnich, Arnold ;
Boileau, Catherine ;
Martinez, Maria .
PLOS GENETICS, 2011, 7 (07)
[5]  
Altorok N., 2014, ANN RHEUM DIS
[6]  
Altorok N., 2014, RHEUMATOLOGY
[7]   Course of the Modified Rodnan Skin Thickness Score in Systemic Sclerosis Clinical Trials Analysis of Three Large Multicenter, Double-Blind, Randomized Controlled Trials [J].
Amjadi, Sogol ;
Maranian, Paul ;
Furst, Daniel E. ;
Clements, Philip J. ;
Wong, Weng Kee ;
Postlethwaite, Arnold E. ;
Khanna, Puja P. ;
Khanna, Dinesh .
ARTHRITIS AND RHEUMATISM, 2009, 60 (08) :2490-2498
[8]   Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria [J].
Andreasson, K. ;
Saxne, T. ;
Bergknut, C. ;
Hesselstrand, R. ;
Englund, M. .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (10) :1788-1792
[9]   PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC-SCLEROSIS (SCLERODERMA) [J].
不详 .
ARTHRITIS AND RHEUMATISM, 1980, 23 (05) :581-590
[10]  
Arnett FC, 2001, ARTHRITIS RHEUM-US, V44, P1359, DOI 10.1002/1529-0131(200106)44:6<1359::AID-ART228>3.0.CO